azacitidine has been researched along with tetrahydrouridine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (43.75) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Wentworth, DF; Wolfenden, R | 1 |
| Abbasi, MM; Beisler, JA; Voytek, P; Wolpert-DeFilippes, MK | 1 |
| Cihák, A; Veselý, J | 1 |
| Gaudio, L; Kelly, CJ; Schoenemann, PT; Wodinsky, I; Yesair, DW | 1 |
| Laliberté, J; Marquez, VE; Momparler, RL | 1 |
| Kaysen, J; Kufe, D; Spriggs, D | 1 |
| DeSimone, J; Hall, L; Heller, P; Molokie, RE; Zwiers, D | 1 |
| Coles, E; Gaudio, L; Kelly, CJ; Yesair, DW | 1 |
| Cournoyer, D; Eliopoulos, N; Momparler, RL | 1 |
| Achberger, S; Alcazar, O; Aldrich, W; Hu, Z; Negrotto, S; Saunthararajah, Y; Triozzi, P | 1 |
| Chan, KK; Covey, J; Desimone, J; Engelke, KJ; Lavelle, D; Ling, Y; Mahfouz, R; Negrotto, S; Ng, KP; Ruiz, MA; Saunthararajah, Y; Smith, N; Terse, P; Vaitkus, K | 1 |
| Ebrahem, Q; Mahfouz, RZ; Ng, KP; Saunthararajah, Y | 1 |
| Alt, J; Delahanty, G; Duvall, B; Ferraris, D; Huang, KC; Mistry, B; Redkar, S; Rojas, C; Rowbottom, C; Sanders, K; Schuck, E; Slusher, BB; Tsukamoto, T | 1 |
| DeSimone, J; Engel, JD; Fada, S; Gordeuk, V; Gowhari, M; Hassan, J; Hsieh, M; Hsu, LL; Ibanez, V; Jacobberger, J; Krauz, L; Lavelle, D; Molokie, R; Ng, KP; Pacelli, D; Pacini, M; Phelps, M; Radivoyevitch, T; Ruiz, MA; Rump, M; Saraf, S; Saunthararajah, Y; Tisdale, JF; Woost, P | 1 |
| Chen, J; Dean, R; Dever, M; Fada, S; Hill, B; Jagadeesh, D; Lindner, D; Morrison, A; Parameswaran, N; Pohlman, B; Radivoyevitch, T; Robinson, S; Saunthararajah, Y; Smith, M | 1 |
| Borlak, J; Liu, L; Tang, Z | 1 |
2 trial(s) available for azacitidine and tetrahydrouridine
| Article | Year |
|---|---|
Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
Topics: Adult; Anemia, Sickle Cell; Azacitidine; Decitabine; Drug Therapy, Combination; Enzyme Inhibitors; Epigenesis, Genetic; Female; Fetal Hemoglobin; Gene Expression Regulation; Gene Silencing; Humans; Male; Middle Aged; Tetrahydrouridine; Treatment Outcome; Young Adult | 2017 |
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Epigenesis, Genetic; Humans; Lymphoma; Pilot Projects; Tetrahydrouridine | 2021 |
14 other study(ies) available for azacitidine and tetrahydrouridine
| Article | Year |
|---|---|
On the interaction of 3,4,5,6-tetrahydrouridine with human liver cytidine deaminase.
Topics: Azacitidine; Binding Sites; Cytarabine; Cytidine Deaminase; Humans; Kinetics; Liver; Nucleoside Deaminases; Protein Binding; Tetrahydrouridine; Uridine | 1975 |
Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine.
Topics: Animals; Azacitidine; Cell Division; Cells, Cultured; Cytidine; Cytidine Deaminase; Deoxycytidine; Drug Synergism; Kinetics; Leukemia L1210; Oxidative Phosphorylation; Tetrahydrouridine; Thymidine; Uridine | 1977 |
Transformation of 5-aza-2'-(3H)deoxycytidine in Escherichia coli.
Topics: Azacitidine; Deoxycytidine; Escherichia coli; Tetrahydrouridine; Uracil | 1977 |
Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
Topics: Animals; Azacitidine; Drug Therapy, Combination; Female; Infusions, Parenteral; Injections, Intraperitoneal; Leukemia L1210; Mice; Tetrahydrouridine; Uridine | 1978 |
Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
Topics: Antineoplastic Agents; Azacitidine; Azepines; Cytarabine; Cytidine; Cytidine Deaminase; Deamination; Decitabine; Humans; Kinetics; Pyrimidine Nucleosides; Tetrahydrouridine | 1992 |
Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells.
Topics: Azacitidine; Breast Neoplasms; Cell Line; Cell Survival; Decitabine; Deoxycytidine; Deoxyuridine; DNA, Neoplasm; Floxuridine; Humans; Methylation; RNA, Neoplasm; Tetrahydrouridine | 1986 |
Tetrahydrouridine, cytidine analogues, and hemoglobin F.
Topics: Agranulocytosis; Animals; Azacitidine; Cytidine Deaminase; Decitabine; Fetal Hemoglobin; Gene Expression Regulation; Globins; Granulocytes; Papio; Tetrahydrouridine; Uridine | 1985 |
Characterization of the urinary metabolites of 5-azacytidine in mice.
Topics: Animals; Azacitidine; Biotransformation; Male; Mice; Mice, Inbred Strains; Tetrahydrouridine | 1980 |
Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
Topics: 3T3 Cells; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Colony-Forming Units Assay; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; DNA, Complementary; Drug Resistance; Enzyme Inhibitors; Fibroblasts; Gemcitabine; Gene Transfer Techniques; Genetic Vectors; Humans; Mice; Phenotype; Retroviridae; Tetrahydrouridine | 1998 |
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Base Sequence; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor Proteins; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; Sequence Analysis, DNA; SOX9 Transcription Factor; Tetrahydrouridine; Tumor Suppressor Protein p53; Up-Regulation | 2012 |
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
Topics: Administration, Oral; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; Biological Availability; Decitabine; DNA Damage; DNA Methylation; Drug Interactions; Female; Hematopoietic Stem Cells; Inactivation, Metabolic; Injections, Intravenous; Injections, Subcutaneous; Mice; Papio anubis; Tetrahydrouridine | 2012 |
High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytidine Deaminase; Decitabine; Humans; Leukemia, Myeloid; Liver; Liver Neoplasms; Mice; Mice, Knockout; Tetrahydrouridine; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2012 |
Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.
Topics: Animals; Azacitidine; Biological Availability; Cytidine Deaminase; Decitabine; Drug Design; Drug Stability; Enzyme Inhibitors; Excitatory Postsynaptic Potentials; Fluorine; Gastric Juice; Macaca mulatta; Models, Molecular; Molecular Conformation; Structure-Activity Relationship; Tetrahydrouridine | 2014 |
Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.
Topics: Adenocarcinoma; Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; Cytidine Deaminase; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Prospective Studies; Tetrahydrouridine; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2023 |